Investor Presentaiton
18
Biotechnology
2022 TOTAL REVENUE
Bioprocessing
•
BROADEST PORTFOLIO ACROSS BIOPROCESSING WORKFLOW
Leading positions in upstream & downstream applications
Single-use technologies (SUT) >$1B 2022 revenue
Lab &
Medical
$8.8B
Research
.
cytiva
PALL
Life Sciences
•
BEST-IN-CLASS TECHNICAL SERVICE & SUPPORT
Process development services to move from R&D to commercialization
Local presence in all major regions to support customers
GLOBAL SCALE TO RELIABLY MEET OUR CUSTOMERS' NEEDS
Products and solutions span from lab to production scale
• Current & future expansion plans to help ensure security of supply for customers
Enhancing our value proposition through organic & inorganic investments
Aligning to best serve our customers
DANAHERView entire presentation